Bright Minds Biosciences Inc
Bright Minds Biosciences Inc is a biotechnology company operating in the Health Care sector, engaged in biotechnology activities.
Business. Bright Minds Biosciences Inc (DRUG.CD) is a biotechnology company operating within the Health Care sector. The firm is engaged in biotechnology activities, though specific operating segments and geographic details are not provided. Headquarters location and primary exchange listing information are not specified in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bright Minds Biosciences Inc (DRUG.CD) is a biotechnology company operating within the Health Care sector. The firm is engaged in biotechnology activities, though specific operating segments and geographic details are not provided. Headquarters location and primary exchange listing information are not specified in the available data.
Bright Minds Biosciences Inc maintains a capital structure characterized by minimal leverage, with a debt-to-equity ratio of 0.0 and long-term debt of only CAD 125,780 against total equity of CAD 82,044,920. The company reports a current ratio of 36.1, indicating strong short-term liquidity coverage relative to liabilities. However, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, despite reported cash and equivalents of CAD 86,250. This discrepancy suggests potential off-balance-sheet obligations or classification nuances in the cash position relative to total liabilities of CAD 2,376,620.
Profitability metrics reflect the early-stage nature of the business, with a return on equity of -14.91% and a return on assets of -14.49%. The company recorded an operating income of -CAD 13,901,730 and a net income of -CAD 12,229,350 for the latest period. Cash flow from operations was negative at -CAD 8,691,620, while free cash flow stood at -CAD 12,152,480, indicating significant cash burn typical of pre-revenue or early-revenue biotechnology firms investing in research and development.
- The company operates with a net loss of CAD 12.2 million and negative free cash flow of CAD 12.2 million, reflecting early-stage biotechnology burn rates.
- Leverage is negligible with a debt-to-equity ratio of 0.0, but liquidity risk is rated medium due to negative net cash after debt.
- Dilution risk is assessed as low, with basic and diluted shares outstanding identical at 9.8 million.
- Historical growth data and segment breakdowns are absent, limiting trend analysis and revenue concentration assessment.
- No specific corporate news or management signals are present in the input, only system reconciler logs.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Bright Minds Biosciences Inc Market data — financials · 2026-07-27
- reconciler_enqueue (reconciler) on DRUG.CD · 2026-07-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,05 %$94M
- Investment Managers · as of 2026-03-310,00 %$10M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$8M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Leadership
- Ian B. McdonaldPresident, Chief Executive Officer, Director
Insider activity
- Former 10% Owner · Common SharesSold 109 331 @ $89,50$9,8M · 2026-04-28